Business Wire

Future Toyota Cars to be Powerd by RoboSense LiDAR for Safer Self-Driving

Share

RoboSense, a world-leading provider of Smart LiDAR Sensor Systems, officially announced its partnership with Toyota, the world's best-selling carmaker, on large-scale production with nominated orders for multiple models. With its advanced technology and product advantages in the global LiDAR field, RoboSense has been officially integrated into Toyota's supply chain system.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230207005749/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

RoboSense has been officially integrated into Toyota's supply chain system

Toyota has been No.1 in global sales for three consecutive years since 2020. In 2022, Toyota sold 10.5 million vehicles, winning the "Best-Selling Automaker" crown. Since the start of the 21st century, Toyota has fully carried out localized production and sales in China and established joint ventures with FAW, GAC, BYD and other domestic auto brands. As a model world-famous joint-venture car brand, a number of featured products of FAW Toyota post strong sales globally, serving as stable support for Toyota to top the global sales ranking. RoboSense and Toyota will collaborate in-depth on a number of top-selling FAW Toyota models.

By equipping them with the RS-LiDAR-M series LiDAR ("M-series" for short), RoboSense will empower Toyota models with accurate perception capabilities, guard the driving safety of Toyota's intelligent models, and promote the series production and large-scale application of LiDAR in the automotive industry. The M-series is a featured automotive-grade, revolutionary product from RoboSense for vehicle series production. It is the only second-generation smart solid-state LiDAR in the world to achieve the automotive-grade series production. It adopts a revolutionary chip-based 2D scanning solution, which boasts supreme performance and reliability. At present, the M-series has obtained nominated orders for more than 50 models from nearly 20 car companies, including Toyota, with an expected order volume of more than 10 million units.

Toyota has nearly a century of history developing durable, stable and reliable vehicles, which made it the "global top seller". RoboSense leverages its professional CNAS accredited lab and the largest production and intelligent manufacturing system in the industry to satisfy Toyota's high-quality product and large-scale production requirements.

Prior to this, RoboSense had reached partnership with BYD, a world-leading pioneer in new energy vehicles, on various models. This in-depth partnership between RoboSense and Toyota means that RoboSense has become a part of the supply chain system of both best-selling car brands worldwide at the same time, making it a leader in the global LiDAR market.

About RoboSense

RoboSense (Suteng Innovation Technology Co., Ltd.) is a world-leading provider of Smart LiDAR Sensor Systems. With a complete portfolio of LiDAR sensors, AI perception and IC chipsets, RoboSense transforms conventional 3D LiDAR sensors with comprehensive data analysis and interpretation systems. Its mission is to innovate outstanding hardware and AI capabilities to create smart solutions that enable robots, including autonomous vehicles, to have perception capabilities superior to humans.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Press
Grace Ye
media@robosense.cn

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Galderma Welcomes Increased Equity Investment From L’Oréal8.12.2025 08:05:00 EET | Press release

Galderma Group AG (SIX:GALD), the pure-play dermatology category leader, today announced that L’Oréal Groupe intends to increase its equity investment in the company, acquiring an additional 10% stake from Sunshine SwissCo GmbH (a consortium led by EQT, Abu Dhabi Investment Authority (ADIA), and Auba Investment Pte. Ltd., acting as sellers). Following the transaction, which is subject to customary approvals, L’Oréal’s total shareholding in Galderma will rise to 20%, building on its initial investment made in August 2024. The transaction is expected to close in Q1 2026. In connection with this increased investment, Galderma will consider nominating two non-independent board candidates from L’Oréal, replacing the board members representing the consortium led by EQT, at the 2026 Annual General Meeting. Additionally, Galderma and L’Oréal aim at exploring additional scientific research projects of mutual interest. This ongoing collaboration brings together Galderma’s scientific leadership i

Ant International Wins Champion of NeurIPS Competition of Fairness in AI Face Detection8.12.2025 05:37:00 EET | Press release

Ant International, a leading global digital payment, digitisation, and financial technology provider, has won first place at the NeurIPS Competition of Fairness in AI Face Detection. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251207210856/en/ Ant International’s solution takes top spot at the NeurIPS Competition of Fairness in AI Face Detection, emerging first among over 2,100 submissions from 162 teams globally. AI Fairness enhances Financial Security Studies by the National Institute of Standards and Technology (NIST) show that many commercial facial recognition algorithms have significantly higher error rates for women and people of colour largely due to underrepresentation in datasets AI algorithms are trained on. Biased algorithms lead to unfair denials of service and create security vulnerabilities. The competition at the Conference on Neural Information Processing Systems, among the world’s most prestigious AI con

Sonrotoclax Data at ASH 2025 Confirm Foundational Potential Across B-cell Malignancies8.12.2025 01:00:00 EET | Press release

BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new data on sonrotoclax, a next-generation investigational BCL2 inhibitor, demonstrating meaningful clinical benefit as monotherapy and in combination across B-cell malignancies. These data were featured at the 67th American Society of Hematology (ASH) Annual Meeting & Exposition in Orlando, Florida. The five presentations highlight durable responses in heavily pretreated patients with relapsed/refractory (R/R) mantle cell lymphoma (MCL) and additional studies showing deep, rapid, and sustained undetectable minimal residual disease (uMRD) rates with sonrotoclax-based combinations in patients with treatment-naive chronic lymphocytic leukemia (CLL), highlighting the foundational potential of this medicine. “The data we’re presenting at ASH 2025 are redefining what physicians can expect from sonrotoclax as a next-generation BCL2 inhibitor,” said Amit Agarwal, M.D., Ph.D., Chief Medical

Hemato-Oncology Trials: AOP Health Presents New Results at Top Congress ASH7.12.2025 18:00:00 EET | Press release

AOP Health continues to advance its clinical research program in myeloproliferative neoplasms, a special group of rare blood cancers. The company, specialized in rare diseases, presented the results of two scientific investigations at the 67th American Society of Hematology Association (ASH) Annual Meeting 2025 held in Orlando, FL, USA. The results provide new insights in treatment strategies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251207587915/en/ Dr. Martin Steinhart, CEO AOP Health; Photo credit: AOP Health/Studio Koekart ROP-ET and BESREMI PASS One of the clinical studies, ROP-ET, examined the use of ropeginterferon alfa-2b in people with essential thrombocythemia (ET), a disease in which the body produces too many platelets. The trial, a prospective, multicenter, single-arm phase III study, investigated the safety and efficacy of ropeginterferon alfa-2b in ET patients unable to receive available cytoreductive th

CoMotion GLOBAL 2025 Launches in Riyadh: Global Mobility Leaders Unite in Saudi Capital to Chart Urban Future7.12.2025 14:00:00 EET | Press release

Riyadh is rapidly becoming one of the world's most ambitious urban mobility laboratories, where next-generation technologies move from blueprint to real-world deployment on city streets at unprecedented scale. CoMotion GLOBAL 2025, the world's most influential gathering of urban mobility leaders, opens today in Riyadh for a three-day summit bringing together innovators from Africa, Asia, Europe, the Americas, and the Middle East. Running December 7-9, the event will explore how electrification, autonomy, AI-enabled transport, and giga-project urbanism are reshaping cities worldwide. The summit will spotlight everything from high-performance EVs and breakthrough autonomous fleets to emerging-market transport solutions and new mobility models, demonstrating how the Kingdom is opening new pathways for global mobility leadership. Strategic Partnerships Powering the Summit CoMotion GLOBAL 2025 is hosted by the Saudi Conventions & Exhibitions General Authority (SCEGA), supported by key Saudi

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye